BioRestorative Therapies/$BRTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioRestorative Therapies
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Ticker
$BRTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
11
ISIN
US0906556065
Website
BRTX Metrics
BasicAdvanced
$15M
-
-$1.48
77.51
-
Price and volume
Market cap
$15M
Beta
77.51
52-week high
$2.28
52-week low
$1.35
Average daily volume
133K
Financial strength
Current ratio
2.237
Quick ratio
2.185
Management effectiveness
Return on assets (TTM)
-54.16%
Return on equity (TTM)
-117.16%
Valuation
Price to revenue (TTM)
41.869
Price to book
2.45
Price to tangible book (TTM)
2.71
Price to free cash flow (TTM)
-1.853
Growth
Revenue change (TTM)
161.54%
Earnings per share change (TTM)
33.95%
3-year revenue growth (CAGR)
107.13%
3-year earnings per share growth (CAGR)
-56.33%
BRTX News
AllArticlesVideos
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
GlobeNewsWire·2 hours ago
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
GlobeNewsWire·4 days ago
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioRestorative Therapies stock?
BioRestorative Therapies (BRTX) has a market cap of $15M as of June 13, 2025.
What is the P/E ratio for BioRestorative Therapies stock?
The price to earnings (P/E) ratio for BioRestorative Therapies (BRTX) stock is 0 as of June 13, 2025.
Does BioRestorative Therapies stock pay dividends?
No, BioRestorative Therapies (BRTX) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next BioRestorative Therapies dividend payment date?
BioRestorative Therapies (BRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioRestorative Therapies?
BioRestorative Therapies (BRTX) has a beta rating of 77.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.